After failed FSGS bid, Travere wins full FDA approval for Filspari in IgAN
The company had focused its resources on Filspari’s launch in IgAN after the US FDA snubbed the therapy in another rare kidney disorder.
The company had focused its resources on Filspari’s launch in IgAN after the US FDA snubbed the therapy in another rare kidney disorder.
What's Your Reaction?
